IL-33/ST2 signalling in pediatric food allergy and eosinophilic gastrointestinal disorders: a systematic review of human and preclinical evidence
5 affiliations
- 1Doctoral School, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Târgu Mures, Targu Mures, Romania
- 2Pediatric Clinic I, County Emergency Hospital of Targu Mures, Targu Mures, Romania
- 3Department of Pediatrics 3, “George Emil Palade” University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Târgu Mures, Romania
- 4Department of Internal Medicine, County Emergency Hospital of Targu Mures, Targu Mures, Romania
- 5Department of Pediatrics 1, “George Emil Palade” University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, Târgu Mures, Romania
Abstract
Background: Interleukin-33 (IL-33) is an epithelial-derived member of the IL-1 cytokine family that functions as an alarmin and signals through the ST2 receptor, upstream of type 2 inflammation. Together with thymic stromal lymphopoietin (TSLP) and IL-25, it constitutes an epithelial alarmin triad that orchestrates barrier-related immune responses. Despite substantial mechanistic data, the specific role of IL-33 as a biomarker and therapeutic target in pediatric food-related allergic disease remains insufficiently defined.
Objective: This systematic review aims to synthesize current evidence on serum and tissue IL-33 in pediatric IgE-mediated food allergy and eosinophilic gastrointestinal disorders (EGIDs), to delineate its association with disease severity, clinical phenotype and oral immunotherapy (OIT) outcomes, and to critically appraise the IL-33/ST2 axis as a candidate biomarker and therapeutic target within the broader epithelial alarmin network.
Methods: A systematic search of PubMed/MEDLINE, Web of Science, Scopus and the Cochrane Library (2010–2026) identified pediatric clinical studies quantifying IL-33 or IL-33/ST2 in food allergy or EGIDs, alongside murine and in vitro studies directly interrogating IL-33-dependent mechanisms in food allergy models. Eligible studies were screened and extracted according to predefined PICO criteria.
Results: Fourteen studies fulfilled the inclusion criteria (four pediatric clinical cohorts, ten direct preclinical murine or in vitro studies). Across murine models, keratinocyte-derived IL-33 consistently activated a skin-to-gut axis driving intestinal mast-cell expansion and IgE-independent food anaphylaxis, which was abrogated by genetic or pharmacologic ST2 blockade. In a small case-control study of nine children with eosinophilic gastroenteritis, serum IL-33 and TSLP were increased during active disease and declined after dietary elimination. In pediatric eosinophilic esophagitis, IL-33 was increased in tissue but not consistently in serum. Conversely, serum IL-33 demonstrated limited discriminatory value in IgE-mediated food allergy.
Conclusions: IL-33 emerges as a context-dependent yet non-redundant component of the epithelial alarmin circuitry in pediatric food-related allergic disease, as candidate biomarker of epithelial inflammation in pediatric EGIDs. However, current clinical evidence is limited and requires validation in larger prospective cohorts.
Related
- Early recognition of eosinophilic granulomatosis with polyangiitis in outpatient settings: musculoskeletal and gastrointestinal clues beyond respiratory disease
- Drug-induced gastrointestinal toxicity: from pathophysiological mechanisms to human-relevant preclinical models
- Antibiofilm and Quorum-sensing Agents Against Pseudomonas aeruginosa and Staphylococcus aureus: a Systematic Review of Preclinical Studies, 2022-2026
- Motor Evoked Potentials in Preclinical Models of Spinal Cord Injury and Stroke in Rodents: A Systematic Review.
- Epigenetic mechanisms of Non-Invasive Brain Stimulation: A Systematic Review of Human and Preclinical Evidence
BibTeX
@article{grama2026il33st2,
title = {{IL-33/ST2 signalling in pediatric food allergy and eosinophilic gastrointestinal disorders: a systematic review of human and preclinical evidence}},
author = {Monica Grama and Maria Oana Săsăran and Ana Stan Muntean and Delia Coman and Alina Ivasko and Cristina Oana Mărginean},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1961426},
url = {https://doi.org/10.3389/fimmu.2026.1961426},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - IL-33/ST2 signalling in pediatric food allergy and eosinophilic gastrointestinal disorders: a systematic review of human and preclinical evidence
AU - Monica Grama
AU - Maria Oana Săsăran
AU - Ana Stan Muntean
AU - Delia Coman
AU - Alina Ivasko
AU - Cristina Oana Mărginean
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1961426
UR - https://doi.org/10.3389/fimmu.2026.1961426
AB - Background: Interleukin-33 (IL-33) is an epithelial-derived member of the IL-1 cytokine family that functions as an alarmin and signals through the ST2 receptor, upstream of type 2 inflammation. Together with thymic stromal lymphopoietin (TSLP) and IL-25, it constitutes an epithelial alarmin triad that orchestrates barrier-related immune responses. Despite substantial mechanistic data, the specific role of IL-33 as a biomarker and therapeutic target in pediatric food-related allergic disease remains insufficiently defined. Objective: This systematic review aims to synthesize current evidence on serum and tissue IL-33 in pediatric IgE-mediated food allergy and eosinophilic gastrointestinal disorders (EGIDs), to delineate its association with disease severity, clinical phenotype and oral immunotherapy (OIT) outcomes, and to critically appraise the IL-33/ST2 axis as a candidate biomarker and therapeutic target within the broader epithelial alarmin network. Methods: A systematic search of PubMed/MEDLINE, Web of Science, Scopus and the Cochrane Library (2010–2026) identified pediatric clinical studies quantifying IL-33 or IL-33/ST2 in food allergy or EGIDs, alongside murine and in vitro studies directly interrogating IL-33-dependent mechanisms in food allergy models. Eligible studies were screened and extracted according to predefined PICO criteria. Results: Fourteen studies fulfilled the inclusion criteria (four pediatric clinical cohorts, ten direct preclinical murine or in vitro studies). Across murine models, keratinocyte-derived IL-33 consistently activated a skin-to-gut axis driving intestinal mast-cell expansion and IgE-independent food anaphylaxis, which was abrogated by genetic or pharmacologic ST2 blockade. In a small case-control study of nine children with eosinophilic gastroenteritis, serum IL-33 and TSLP were increased during active disease and declined after dietary elimination. In pediatric eosinophilic esophagitis, IL-33 was increased in tissue but not consistently in serum. Conversely, serum IL-33 demonstrated limited discriminatory value in IgE-mediated food allergy. Conclusions: IL-33 emerges as a context-dependent yet non-redundant component of the epithelial alarmin circuitry in pediatric food-related allergic disease, as candidate biomarker of epithelial inflammation in pediatric EGIDs. However, current clinical evidence is limited and requires validation in larger prospective cohorts.
SN - 1664-3224
ER -